by Dennis Crouch
In an important opinion exploring the relationship between patent validity and after-arising technology, the Federal Circuit has reversed a district court’s invalidation of a pharmaceutical patent covering Novartis’s blockbuster heart failure drug Entresto. Novartis Pharmaceuticals Corp. v. Torrent Pharma Inc., Nos. 2023-2218, 2023-2220, 2023-2221 (Fed. Cir. Jan. 10, 2025).
To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.
